Early Prostate Cancer
clinical trial
The Early Prostate Cancer (EPC) programme was a large clinical trial programme of monotherapy with the nonsteroidal antiandrogen bicalutamide (Casodex) plus standard care versus standard care alone in men with early prostate cancer. It was started in August 1995, with the first analysis published in 2002 and the final follow-up published in 2010. The programme consisted of three large randomized, double-blind, placebo-controlled trials in which a total of 8,113 men with localized or locally advanced prostate cancer were treated with 150 mg/day bicalutamide plus standard care (watchful waiting, radical prostatectomy, or radiation therapy) (n=4052) or given placebo (standard care alone) (n=4061). It constituted the largest clinical trial of prostate cancer treatment to have ever been conducted at the time.
The three trials in the EPC programme were as follows:
Trial 23 (North America; n=3292)
Trial 24 (Europe, Australia, Israel, South Africa, and Mexico; n=3603)
Trial 25 (Scandinavia; n=1218) (also known as the Scandinavian Prostate Cancer Group-6 (SPCG-6) study)
Several combined follow-up papers of the EPC programme results were published, including at median 3.0 years in August 2002, median 5.4 years in November 2004, median 7.4 years in February 2006, and median 9.7 years in April 2010.
The EPC programme found that bicalutamide was effective in treating locally advanced prostate cancer. Conversely, it was not effective for localized prostate cancer, where there was instead a statistically insignificant trend toward reduced overall survival with bicalutamide therapy (at median 7.4 years follow-up: HRTooltip hazard ratio = 1.16; 95% CITooltip confidence interval = 0.99–1.37; PTooltip p-value = 0.07). The increased mortality with bicalutamide in men with localized prostate cancer was however statistically significant at certain follow-ups in the Trial 25/SPCG-6 substudy of the EPC programme. The preceding findings led to the withdrawal of pre-existing approval of bicalutamide for localized prostate cancer in the United Kingdom and Canada.
Liver safety is an important concern with bicalutamide.
“Early Prostate Cancer” enters the record as clinical trial. Crown Archives preserves that source wording while asking what Early, Prostate and Cancer can confirm, complicate or overturn.
Why this record matters
“Early Prostate Cancer” is worth following because a concise public description often conceals a longer documentary argument. Here, Early, Prostate and Cancer provides the most credible route into that argument.
The citation trail is more important than the brevity of the summary: it shows where individual claims can be examined in context. The source revision retrieved here is dated Sep 2, 2026. The linked authority identifier is Q113581937. None of the 0 selected statements returned an explicit reference. The first chronological checks are 1995, 2002, 2010 and 1218.
Overview language is designed for orientation and should not be treated as a substitute for the evidence cited beneath it. The source lead contains qualifying language; that uncertainty should survive quotation, summary and reuse. Authority statements aid reconciliation but still require their own references, qualifiers and ranks to be checked.
How to read it
Use the entry as an orientation point, then follow its citations and revision history. Names, dates and institutional relationships should be checked against the original record.
- Subject orientation
- Search vocabulary
- Locating named sources
The closest primary source, responsible institution and strongest cited specialist reference.
Three-step research path
- Establish the record: confirm the title “Early Prostate Cancer”, its source revision and the description used here.
- Expand the search: follow Early Prostate Cancer primary sources, Early Prostate Cancer archive and Early research across catalogues and specialist indexes.
- Test the account: compare the strongest cited source with the responsible institution’s current record and note any disagreement.
Questions for further research
- Which source most directly establishes the central claim about “Early Prostate Cancer”?
- What terminology or title could unlock a more precise catalogue search?
- Which institution is responsible for the underlying evidence?
Search terms from this dossier
This entry incorporates text from “Early Prostate Cancer” on English Wikipedia. Contributors are listed in the page history. Text is available under the Creative Commons Attribution-ShareAlike 4.0 License. Selected authority identifiers and statements are retrieved from Wikidata under CC0; their references and qualifiers remain part of the verification path.